ETC

Recommend
Index
  • Tenelia M SR Tab. 10/500mg

    Tenelia M SR Tab. 10/500mg

    Ingredient

    Teneligliptin Hydrobromide Hydrate/Metformin Hydrochloride

    Content

    Teneligliptin Hydrobromide Hydrate 15.5mg (10mg as Teneligliptin), Metformin Hydrochloride 500mg

    Indication

    This drug is administered as an adjunct to diet and exercise to adult patients with type 2 diabetes whom combined therapy of teneligliptin and metformin is appropriate.

    – Patients who sufficient glucose control cannot be achieved with metformin monotherapy
    – Replacing teneriglitin and metformin combined therapy
    – sulfonylureas and this drug can be administered in combined therapy when sufficient glucose control cannot be achieved with metformin and sulfonylurea combined therapy.

  • Tenelia M SR Tab. 10/750mg

    Tenelia M SR Tab. 10/750mg

    Ingredient

    Teneligliptin Hydrobromide Hydrate/Metformin Hydrochloride

    Content

    Teneligliptin Hydrobromide Hydrate 15.5mg (10mg as Teneligliptin), Metformin Hydrochloride 750mg

    Indication

    This drug is administered as an adjunct to diet and exercise to adult patients with type 2 diabetes whom combined therapy of teneligliptin and metformin is appropriate.

    – Patients who sufficient glucose control cannot be achieved with metformin monotherapy
    – Replacing teneriglitin and metformin combined therapy
    – sulfonylureas and this drug can be administered in combined therapy when sufficient glucose control cannot be achieved with metformin and sulfonylurea combined therapy.

  • Tenelia M SR Tab. 20/1000mg

    Tenelia M SR Tab. 20/1000mg

    Ingredient

    Teneligliptin Hydrobromide Hydrate/Metformin Hydrochloride

    Content

    Teneligliptin Hydrobromide Hydrate 31mg (20mg as Teneligliptin), Metformin Hydrochloride 1000mg

    Indication

    This drug is administered as an adjunct to diet and exercise to adult patients with type 2 diabetes whom combined therapy of teneligliptin and metformin is appropriate.

    – Patients who sufficient glucose control cannot be achieved with metformin monotherapy
    – Replacing teneriglitin and metformin combined therapy
    – sulfonylureas and this drug can be administered in combined therapy when sufficient glucose control cannot be achieved with metformin and sulfonylurea combined therapy.

  • Tenelia Tab. 20mg

    Tenelia Tab. 20mg

    Ingredient

    Teneligliptin Hydrobromide Hydrate

    Content

    Teneligliptin Hydrobromide Hydrate 31mg (20mg as Teneligliptin)

    Indication

    This drug is administered as an adjunct to diet and exercise to improve the glucose control of patients with type 2 diabetes.
    1. This drug is administered as a monotherapy
    2. This drug is administered as a combined therapy in the following case.
    – This drug is administered as a combined therapy if sufficient glucose control cannot be achieved with metformin monotherapy.
    – This drug is administered as a combined therapy if sufficient glucose control cannot be achieved with Metformin and Sulfonylurea combination therapy

  • Teveten Plus Tab.

    Teveten Plus Tab.

    Ingredient

    Eprosartan Mesylate/Hydrochlorothiazde

    Content

    600mg

    Indication

    Management of essential hypertension which is not controlled with eprosartan monotherapy

  • Teveten Tab. 600mg

    Teveten Tab. 600mg

    Ingredient

    Eprosartan Mesylate

    Content

    600mg as Eprosartan

    Indication

    Treatment of essential hypertension.

  • Tracleer Tab. 62.5mg

    Tracleer Tab. 62.5mg

    Ingredient

    Bosentan Hydrate

    Content

    64.541mg (62.5mg as Bosentan)

    Indication

    1) Treatment of pulmonary artery hypertension (PAH) (WHO Group I) in adults with WHO-FC III or IV symptoms to improve exercise ability
    2) Delay the onset of clinical deterioration treatment of PAH (WHO Group 1) in adults with WHO-FC II
    3) Reduction of the number of new digital ulcers (DUs) cases in patients with systemic ongoing DU disease caused by systemic sclerosis (SSc)

  • Trental SR Tab. 400

    Trental SR Tab. 400

    Ingredient

    Pentoxifylline

    Content

    400mg

    Indication

    1) Improvement of cerebral circulation disorder (ischemia or post stroke symptoms and symptoms of cerebral arteriosclerosis like dizziness, headache, amnesia, and so on)
    2) Improvement of eye circulation disorder
    3) Improvement of peripheral arterial circulation disorder (Intermittent claudication, pain at rest, diabetic angiopathy, kraurosis, and vascular neuropathy)

  • Triapin Tab.

    Triapin Tab.

    Ingredient

    Felodipine/Ramipril

    Content

    2.5mg/2.5mg, 5mg/5mg

    Indication

    Treatment of essential hypertension.

  • Tritace Protect Tab.

    Tritace Protect Tab.

    Ingredient

    Hydroxypropylmethylcellulose-coated Ramipril Granule

    Content

    11.765mg (10mg as Ramipril)

    Indication

    1) Treatment of hypertension
    2) Treatment of heart failure post myocardial infarction
    3) Reduction in risk of death or the need for revascularization from myocardial infarction, stroke, cardiovascular disease in patients over 55 years of age with clinical evidence of cardiovascular disease (myocardial infarction, unstable angina, past history of polyvascular coronary bypass graft or polyvascular percutaneous coronary angioplasty), stroke or peripheral vascular disease. Also reduction in risk of death or the need for revascularization from myocardial infarction, stroke, cardiovascular disease in diabetic patients over 55 years of age who have one or more of the following clinical symptoms: Hypertension (systolic blood pressure exceeds 160mmHg or diastolic blood pressure exceeds 90 mmHg), high total cholesterol level (above 5.2 mmol/L), low high-density lipoprotein level (less than 0.9 mmol/L), smoker, history of microalbuminuria or past vascular disease
    4) Treatment of the following clinical symptoms in diabetic patients: Early nephropathy with microalbuminuria (30­300mg/24h), overt glomerular nephropathy, proteinuria (>500mg/24h)
    – Treatment of non-diabetic overt glomerular nephropathy (when creatinine clearance is 20-70 mL/min) or proteinuria (≥3g/24h)

TOP